<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="63652">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767337</url>
  </required_header>
  <id_info>
    <org_study_id>FGN-NSR-2012-002</org_study_id>
    <nct_id>NCT01767337</nct_id>
  </id_info>
  <brief_title>Intracutaneous Delivery of Varied Dose Volumes of Saline</brief_title>
  <official_title>Exploratory Evaluation of Healthy Subjects Receiving Varied Dose Volumes of Saline Delivered by a Non-Significant Risk Investigational Device Utilizing a Micro-Needle Array</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FluGen Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pearl Pathways, LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Accelovance Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FluGen Inc</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate intracutaneous delivery of 0.1, 0.25 and 0.5 milliliter volumes of
      saline from the FLUGEN 101.2 investigational microneedle-based device.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>The primary objective is to evaluate the safety and tolerability/reactogenicity of various saline volumes delivered from the FLUGEN 101.2 microneedle-based device as evidenced by change of dose site appearance over time.</measure>
    <time_frame>30 minutes, 24 hours, ~ 1 week</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Observe injection sites for change of appearance post-dose including initial wheal formation and subsequent resolution.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>A secondary objective of this study is to evaluate the mechanical elimination of fluid from the device.</measure>
    <time_frame>3 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluate ability of device to dispense targeted dose volume.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Intracutaneous Drug Delivery</condition>
  <arm_group>
    <arm_group_label>Delivery volume</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Deliver 0.1, 0.25 and 0.5 mL volumes of saline via FLUGEN 101.2 device to non-overlapping injection sites.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>FLUGEN 101.2 microneedle-based delivery device</intervention_name>
    <arm_group_label>Delivery volume</arm_group_label>
    <other_name>FLUGEN 101.2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Able to read and/or understand and sign the Informed Consent form

        Exclusion Criteria:

          -  Medical history of acute or chronic skin disease

          -  Active skin allergy or acute skin infection, presence of tattoo(s), scars, sunburn or
             skin abnormalities at any prospective injection site

          -  Hirsute at any prospective injection site

          -  Diabetes

          -  High levels of anxiety or depression or history of psychosis

          -  Abuse of alcohol or use of other drugs of abuse including tobacco

          -  Pregnant or breastfeeding women

          -  Any medical condition that may interfere with study protocol adherence including
             completion of study activities

          -  Foreseeable inability to complete the study as scheduled.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renee Herber</last_name>
    <role>Study Director</role>
    <affiliation>FluGen Inc</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Murray A Kimmel, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>Accelovance Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Accelovance Inc</name>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <zip>32935</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 10, 2013</lastchanged_date>
  <firstreceived_date>January 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microneedle-based delivery</keyword>
  <keyword>hollow microneedle</keyword>
  <keyword>intracutaneous</keyword>
  <keyword>drug delivery</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
